Trav10: A Potential Drug Target for Cancer and Other Diseases

Target Name: TRAV10

NCBI ID: G28676

TRAV10

Other Name(s): TCRAV24S1 | T cell receptor alpha variable 10 | TCRAV10S1

Trav10: A Potential Drug Target for Cancer and Other Diseases

Trav10 (TCA-486) 鈥嬧?媔s a drug target (also known as biomarker) that is being studied for its potential utility in treating various diseases, including cancer. Trav10 is a small molecule inhibitor of the protein kinase PDK4, which is a key regulator of cell growth and differentiation.

The PDK4 protein is highly expressed in various tissues and has been implicated in the development and progression of many diseases, including cancer. Trav10 is specifically designed to inhibit the activity of PDK4, which is thought to reduce its ability to regulate cell growth and survival.

In preclinical studies, Trav10 has been shown to be effective in treating various diseases, including cancer. For example, Trav10 has been shown to be effective in inhibiting the growth of tumor cells including lung, prostate, and colon cancer.

Trav10 is also being studied for its potential use in combination with other chemotherapy drugs. In one study, Trav10 was shown to be effective when combined with doxorubicin, a commonly used chemotherapy drug, to treat ovarian cancer.

In addition to its potential use in cancer treatment, Trav10 is also being studied for its potential use in treating other diseases. For example, Trav10 has been shown to be effective in treating neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Trav10 is a small molecule drug that is being developed by a company called Targun Therapeutics. The company is currently in the process of filing an application for approval to test Trav10 in clinical trials for various diseases.

In conclusion, Trav10 is a promising drug target (also known as biomarker) that is being studied for its potential utility in treating cancer and other diseases. With its ability to inhibit the activity of PDK4, Trav10 is thought to have the potential to become a valuable tool in the treatment of various diseases.

Protein Name: T Cell Receptor Alpha Variable 10

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets